EVOTEC AG (FRA:EVT) Evotec SE to acquire Just Biotherapeutics, Inc.

Transparency directive : regulatory news

20/05/2019 22:24

DGAP-Ad-hoc: Evotec SE / Key word(s): Takeover
Evotec SE to acquire Just Biotherapeutics, Inc.

20-May-2019 / 22:24 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years. The acquisition of 100% of the issued and outstanding equity interests of the company will be paid in cash.

Just.Bio is a unique technology company that integrates highly synergistic scientific expertise and technologies for design, development, and manufacturing of biologics. The acquisition grows Evotec's business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics, and infectious diseases. Just.Bio has approx. 90 employees, mainly scientists, all working at a state-of-the-art discovery, development and manufacturing facility in Seattle, WA, USA.

The completion of the transaction is subject to customary closing conditions. The acquisition is expected to close in the second quarter of 2019.

- End of ad hoc notification -

Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)40560 81-242, werner.lanthaler@evotec.com


20-May-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 813731

 
End of Announcement DGAP News Service

813731  20-May-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=813731&application_name=news&site_id=symex


Other stories

06/12/2019 18:33
06/12/2019 15:58
06/12/2019 13:32
06/12/2019 15:01
06/12/2019 16:16
06/12/2019 19:12
06/12/2019 18:17
06/12/2019 11:06
06/12/2019 09:08
06/12/2019 16:26
06/12/2019 10:05
06/12/2019 18:25
06/12/2019 18:40
06/12/2019 15:02
06/12/2019 13:25
06/12/2019 17:55
06/12/2019 15:28
06/12/2019 15:13
06/12/2019 13:30
06/12/2019 14:50
06/12/2019 11:30
05/12/2019 21:40
06/12/2019 17:38
06/12/2019 11:53
06/12/2019 13:03
06/12/2019 16:58
06/12/2019 17:04
06/12/2019 18:01
06/12/2019 17:01
06/12/2019 16:27
05/12/2019 19:18
05/12/2019 10:22
04/12/2019 19:00
05/12/2019 07:00
06/12/2019 09:23
05/12/2019 20:24
06/12/2019 13:18
05/12/2019 15:00